Baidu
map

Am J Trans:研究者将预测肾移植成功的基因缩小到一小段DNA上

2018-02-03 榕榕 来宝网

一项具有里程碑意义的研究将最能预测长期肾移植成功的基因缩小到一小段DNA。

【DNA 的短片段预测肾脏移植的成功】一项具有里程碑意义的研究将最能预测长期肾移植成功的基因缩小到一小段DNA。

收集来自英国和爱尔兰各地的移植数据的第一项研究发现,在供体和受体被称为HLA基因座的DNA部分具有基因匹配的情况下,患者具有长期存活的机会。

在盖伊和圣托马斯NHS基金会信托基金会和伦敦国王学院的国家健康研究所(NIHR)生物医学研究中心(BRC)的领导下,该项目旨在探索如何提高肾脏移植的长期成功率。

以前曾经有人认为有几种基因可以预测肾移植的存活。但是现在研究人员已经表明,只有HLA位点的匹配才能移植成功。

英国和爱尔兰的每个肾脏移植中心都提供了匿名的DNA样本(通过英国和爱尔兰的肾脏移植联盟),欧盟样本也被纳入分析。通过与NHS Blood , Transplant和Wellcome Sanger Institute的重要合作,对这些DNA样本进行分析并与移植和患者生存数据相关联。

由于涉及的协作水平,这个项目花费了十年时间,但研究人员认为,这样的国际性举措是未来改善患者护理的关键。

Graham Lord教授领导了这项研究,他说:

“在这么多的中心之间进行合作是一个真正的挑战,但是它已经得到了回报,因为我们发现这个DNA领域能够告诉我们肾脏供体和受体之间的匹配是否能长期发挥作用。改善移植患者治疗结果,并提供更符合个体患者健康需求的治疗方案。”

尽管大多数这类基因组学研究仅仅使用来自受者或捐赠者的数据,但本研究着眼于来自两种基因组的数据 - 捐献肾脏的患者和接受它的患者。

研究结果表明,可以给患者提供更高水平的个性化治疗,同时减少对免疫抑制治疗的需求,并降低肾移植排斥反应的发生率。像这样的改进可以降低NHS的成本。

原始出处:

Maria P. Hernandez-Fuentes et al, Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study, American Journal of Transplantation (2018). DOI: 10.1111/ajt.14594.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032759, encodeId=8b902032e5999, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Nov 01 16:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656948, encodeId=d56c16569482b, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 06 07:21:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284718, encodeId=f3fa284e1815, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat Feb 03 09:33:51 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284711, encodeId=fc25284e11ac, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 03 09:24:26 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-11-01 stfoxst
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032759, encodeId=8b902032e5999, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Nov 01 16:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656948, encodeId=d56c16569482b, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 06 07:21:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284718, encodeId=f3fa284e1815, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat Feb 03 09:33:51 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284711, encodeId=fc25284e11ac, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 03 09:24:26 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-11-06 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032759, encodeId=8b902032e5999, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Nov 01 16:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656948, encodeId=d56c16569482b, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 06 07:21:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284718, encodeId=f3fa284e1815, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat Feb 03 09:33:51 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284711, encodeId=fc25284e11ac, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 03 09:24:26 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-03 龙胆草

    学习谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2032759, encodeId=8b902032e5999, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Nov 01 16:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656948, encodeId=d56c16569482b, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 06 07:21:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284718, encodeId=f3fa284e1815, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat Feb 03 09:33:51 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284711, encodeId=fc25284e11ac, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 03 09:24:26 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-03 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Kidney Int:看血管紧张素II 1型受体抗体,知儿科肾移植预后!

血管紧张素II 1型受体(AT1R)抗体与成年肾移植中同种异体移植出现较差的结果相关。然而,其对儿童的临床结局影响仍然知之甚少。近期,一项发表在杂志Kidney Int上的研究对这一问题进行了探讨。研究者们评估了一组儿科肾移植受体患者中的AT1R抗体与临床结果、活检结果、炎性细胞因子和HLA供体特异性抗体(DSA)的关系。纵向监测了65例患者的AT1R抗体、HLA DSA、IL-8、TNF-α、I

Am J Transplant:L Tac的肾移植患者中依维莫司谷浓度保持多少效果较好?

2017年9月,发表在《Am J Transplant》上的一项3b期、多中心、随机、开放式标签、非劣效性的研究,探索了接受低剂量他克莫司(L Tac)的肾移植患者中依维莫司(EVR)最佳谷浓度,从而达到疗效和安全性的平衡。研究结果表明:当肾移植接受者联用L Tac时维持EVR谷浓度为3-8 ng/mL,能达到疗效和安全性的平衡。

盘点:欧洲泌尿外科学《European Urology》期刊九月文章一览。

此研究结果表明:相比无病生存的患者,转移性复发患者的ctDNA水平显著升高(P<0.001)。 从开始进行血浆ctDNA检测到术后转移复发的中位时间为101天(0–932 天)。因此,液体活检作为一种新的、敏感度较高的技术可早期检测转移复发和监测治疗反应,同时能够支持临床工作开展和指导医生的治疗决策

2017华西医院肾移植总数481例 全国居首

2017年,华西医院肾移植总数481例,居全国第一。华西医院肾移植的移植物5年存活率达到95%,属世界先进水平。

2017年KDIGO活体肾脏移植供者评估医疗的临床实践指南解读

肾脏移植是治疗终末期肾病(end stage kidney disease,ESKD)的最佳方式,供肾匮乏是当前移植界面临的最大问题。活体肾移植是解决供肾缺乏的重要手段,同时因其具有移植效果优于尸体肾移植等优势而在全世界广泛开展。活体肾移植是一种特殊类型的医疗实践,是为了挽救别人生命而让一个健康供者接受手术及由此带来的短长期风险。因此,如何最大程度的保障供者利益是医学界和法律界最为关注的问题。为帮

JAHA:肾移植术后动脉僵硬度降低!

由此可见,该荟萃分析显示终末期肾脏病患者KTX后整体的动脉硬化程度有所降低。

Baidu
map
Baidu
map
Baidu
map